Clinical Trial

A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
I238A: The purpose of this study is to find out what effects being treated with durvalumab has on cancer. The researchers doing this study also want to evaluate if prednisone (a type of steroid), when given together with durvalumab, can reduce any side effects. I238B: The purpose of this study is to allow patients previously enrolled on a completed CCTG trial to continue treatment with durvalumab (+/- tremelimumab)
Protocol Amendment History 33 amendments
This ClinicalTrials.gov record has been amended 33 times since 2019-02-19; most recent amendment 2026-07-13.
Status change: Not Yet Recruiting → Recruiting 2019-10-22
Trial Details
NCT Number NCT03847649
Lead Sponsor Canadian Cancer Trials Group
Collaborators: AstraZeneca
Conditions Cancer
Enrollment 60 participants
Start Date 2020-03-09
Primary Completion 2030-04-30 (estimated)
Study Completion 2031-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-14